Canada Latent Tuberculosis Infection Detection Market Size, Share & Trends Analysis Report By Test Type (Tuberculin Skin Test, Interferon Gamma Release Assays), By End Use, By Province, And Segment Forecasts, 2022 - 2030
This report can be delivered to the clients within 3 Business Days
Canada Latent Tuberculosis Infection Detection Market Growth & Trends
The Canada latent tuberculosis infection detection market size is expected to reach USD 47.08 million by 2030, according to a new report by Grand View Research, Inc. The market is projected to expand at a CAGR of 6.2% from 2022 to 2030. The rising infection rate of latent TB in the indigenous population and high inbound traveling from the regions where TB is endemic are the major factors increasing the demand for latent tuberculosis infection screening. Moreover, the surge in tuberculosis testing and ongoing research activities to develop novel TB tests is another factor contributing to market expansion.
The increasing incidence of latent tuberculosis infection in the country is expected to fuel the demand for testing. Most people infected with M. tuberculosis remain asymptomatic, however, about 5% of latent TB infections develop into active cases. The goal of public health authorities to test for LTBI and to identify people at high risk of developing TB disease is increasing the demand for tuberculosis testing.
According to data published by the Canadian Medical Association, around 70% of immigrants to Canada come from Asia, Africa, and Latin American countries where TB infection is endemic. Out of these immigrants, around 50% are estimated to have latent tuberculosis infection. Moreover, around two-thirds of reported cases occur in foreign-born individuals in Canada.
Canada’s government is taking favorable initiatives to achieve WHO’s goal to eliminate the disease in the country. It has already achieved the End TB target milestone, an action plan by the WHO to eliminate the disease by 2050. Optimal management of tuberculosis and improvement in healthcare infrastructure is expected to eradicate the disease in the coming years.
Moreover, increasing recommendations for latent TB infection tests for the high-risk population in the country is expected to fuel market growth. The Canadian TB Standards recommend the use of TST and IGRA for the detection of LTBI. IGRAs are preferred to test LTBI in individuals who have taken the BCG vaccine and in groups with poor TST test results. However, TST is mainly recommended when repeated testing is planned.
The screening for LTBI of immigrants and the general population in the country is low. About 2.5% of new immigrants are flagged for surveillance after reaching the country. Medical screening programs for immigrants in Canada do not specifically include screening for LTBI and it is not mentioned in most lists of reportable diseases in the country. The inclusion of LTBI screening in surveillance programs in the country may increase the demand for latent tuberculosis tests in the coming years.
The reimbursement for tests used to detect latent tuberculosis infection is provided for people who have been identified as having contact with active cases or those at high risk of developing active TB. The reimbursement for TB testing is decentralized in the country and is provided at the province level with certain criteria. The government does not recommend latent tuberculosis infection testing and reimbursement to the general population in the country.
Most states in Canada have established three priority strategies for the prevention and management of the disease; identification of people with tuberculosis infection, investigation of contacts of infectious TB, and investigation of the population at high risk for latent TB infection. Such strategies to manage the disease in the country will increase the demand for screening tests for tuberculosis infections.
Canada Latent Tuberculosis Infection Detection Market Report Highlights
Canada Latent Tuberculosis Infection Detection Market Growth & Trends
The Canada latent tuberculosis infection detection market size is expected to reach USD 47.08 million by 2030, according to a new report by Grand View Research, Inc. The market is projected to expand at a CAGR of 6.2% from 2022 to 2030. The rising infection rate of latent TB in the indigenous population and high inbound traveling from the regions where TB is endemic are the major factors increasing the demand for latent tuberculosis infection screening. Moreover, the surge in tuberculosis testing and ongoing research activities to develop novel TB tests is another factor contributing to market expansion.
The increasing incidence of latent tuberculosis infection in the country is expected to fuel the demand for testing. Most people infected with M. tuberculosis remain asymptomatic, however, about 5% of latent TB infections develop into active cases. The goal of public health authorities to test for LTBI and to identify people at high risk of developing TB disease is increasing the demand for tuberculosis testing.
According to data published by the Canadian Medical Association, around 70% of immigrants to Canada come from Asia, Africa, and Latin American countries where TB infection is endemic. Out of these immigrants, around 50% are estimated to have latent tuberculosis infection. Moreover, around two-thirds of reported cases occur in foreign-born individuals in Canada.
Canada’s government is taking favorable initiatives to achieve WHO’s goal to eliminate the disease in the country. It has already achieved the End TB target milestone, an action plan by the WHO to eliminate the disease by 2050. Optimal management of tuberculosis and improvement in healthcare infrastructure is expected to eradicate the disease in the coming years.
Moreover, increasing recommendations for latent TB infection tests for the high-risk population in the country is expected to fuel market growth. The Canadian TB Standards recommend the use of TST and IGRA for the detection of LTBI. IGRAs are preferred to test LTBI in individuals who have taken the BCG vaccine and in groups with poor TST test results. However, TST is mainly recommended when repeated testing is planned.
The screening for LTBI of immigrants and the general population in the country is low. About 2.5% of new immigrants are flagged for surveillance after reaching the country. Medical screening programs for immigrants in Canada do not specifically include screening for LTBI and it is not mentioned in most lists of reportable diseases in the country. The inclusion of LTBI screening in surveillance programs in the country may increase the demand for latent tuberculosis tests in the coming years.
The reimbursement for tests used to detect latent tuberculosis infection is provided for people who have been identified as having contact with active cases or those at high risk of developing active TB. The reimbursement for TB testing is decentralized in the country and is provided at the province level with certain criteria. The government does not recommend latent tuberculosis infection testing and reimbursement to the general population in the country.
Most states in Canada have established three priority strategies for the prevention and management of the disease; identification of people with tuberculosis infection, investigation of contacts of infectious TB, and investigation of the population at high risk for latent TB infection. Such strategies to manage the disease in the country will increase the demand for screening tests for tuberculosis infections.
Canada Latent Tuberculosis Infection Detection Market Report Highlights
- The interferon-gamma release assays segment accounted for the largest revenue share in 2021 owing to the increasing recommendations for IGRAs from various public health authorities
- The tuberculin skin test segment dominated in terms of the number of tests performed due to its higher market penetration and cost-effectiveness of the test
- The diagnostic laboratories segment held the largest revenue share in 2021 followed by the hospitals & clinics segment
- The North Canadian provinces are anticipated to register a faster growth rate during the projected period. The growth of the region is governed by a high portion of the indigenous population and improvement in healthcare facilities
- Key players such as QIAGEN; Oxford Immunotec USA, Inc.; Sanofi; and Abbott held a significant market share
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market Segmentation and Scope
1.1.1 Regional scope
1.1.2 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database:
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective
1.10.2 Objective
1.10.3 Objective
1.10.4 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
CHAPTER 3 CANADA LATENT TUBERCULOSIS INFECTION DETECTION MARKET VARIABLES, TRENDS & SCOPE
3.1 Canada Latent Tuberculosis Infection Detection Market Lineage Outlook
3.1.1 Parent market outlook
3.1.2 Ancillary market
3.2 Penetration & Growth Prospect Mapping for Test Type
3.3 Market Dynamics
3.3.1 Market driver analysis
3.3.1.1 High migration rate in Canada
3.3.1.2 Increasing demand for tuberculosis testing
3.3.1.3 Government initiatives to control tuberculosis
3.3.2 Market restraint analysis
3.3.2.1 Lack of systematic approach to screen tuberculosis
3.3.2.2 Lack of proper recommendations and reimbursement policies
3.4 Regulatory & Reimbursement Scenario
3.5 Canada Latent Tuberculosis Infection Market Analysis Tools
3.5.1 Porter’s Five Forces Analysis
3.5.2 SWOT Analysis; By factor (Political & Legal, Economic, and Technological)
3.6 Prevalence Rate of Latent Tuberculosis Infection, by Province (2018 - 2030) (in Thousands)
3.7 Incidence Rate of Latent Tuberculosis Infection, by Province (2018 - 2030) (in Thousands)
3.8 Estimated Number of Active TB Patients, by Province (2018 - 2020)
3.9 Estimated Number of LTBI Patients, by Province (2018 - 2020)
3.10 Wholesaler’s Cost for the following Tests (2021)
CHAPTER 4 CANADA LATENT TUBERCULOSIS INFECTION DETECTION MARKET: SEGMENT ANALYSIS, BY TEST TYPE, 2018 - 2030 (USD MILLION) (VOLUME, NUMBER OF TESTS)
4.1 Canada Latent Tuberculosis Infection Detection Market: Test Type Movement Analysis
4.2 Segment Dashboard
4.2.1 Tuberculin Skin Test (TST)
4.2.1.1 TST market estimates and forecast, 2018 - 2030 (USD Million)
4.2.1.2 TST market estimates and forecast, 2018 - 2030 Number of Tests in Thousands
4.2.2 Interferon Gamma Release Assays (IGRA)
4.2.2.1 IGRA market estimates and forecast, 2018 - 2030 (USD Million)
4.2.2.2 IGRA market estimates and forecast, 2018 - 2030 Number of Tests in Thousands
CHAPTER 5 CANADA LATENT TUBERCULOSIS INFECTION DETECTION MARKET: SEGMENT ANALYSIS, BY END - USE, 2018 - 2030 (USD MILLION)
5.1 Canada Latent Tuberculosis Infection Detection Market: End - Use Movement Analysis
5.2 Segment Dashboard
5.2.1 Diagnostic Laboratories
5.2.1.1 Diagnostic laboratories market estimates and forecast, 2018 - 2030 (USD Million)
5.2.2 Hospitals & Clinics
5.2.2.1 Hospitals & clinics market estimates and forecast, 2018 - 2030 (USD Million)
5.2.3 Academic & Research Institutions
5.2.3.1 Academic & research institutions market estimates and forecast, 2018 - 2030 (USD Million)
CHAPTER 6 CANADA LATENT TUBERCULOSIS INFECTION DETECTION MARKET: SEGMENT ANALYSIS, BY PROVINCE, 2018 - 2030 (USD MILLION)
6.1 Regional Market Share Analysis, 2021 & 2030
6.2 Canada
6.2.1 Canada Market estimates and forecast, 2018 - 2030 (USD Million) (Volume, Number of Tests)
6.2.2 Alberta
6.2.2.1 Alberta market estimates and forecasts, 2018 - 2030 (USD Million) (Volume, Number of Tests)
6.2.3 British Columbia
6.2.3.1 British Columbia market estimates and forecasts, 2018 - 2030 (USD Million) (Volume, Number of Tests)
6.2.4 Manitoba
6.2.4.1 Manitoba market estimates and forecasts, 2018 - 2030 (USD Million) (Volume, Number of Tests)
6.2.5 New Brunswick
6.2.5.1 New Brunswick market estimates and forecasts, 2018 - 2030 (USD Million) (Volume, Number of Tests)
6.2.6 Nova Scotia
6.2.6.1 Nova Scotia market estimates and forecasts, 2018 - 2030 (USD Million) (Volume, Number of Tests)
6.2.7 Ontario
6.2.7.1 Ontario market estimates and forecasts, 2018 - 2030 (USD Million) (Volume, Number of Tests)
6.2.8 Prince Edward Island
6.2.8.1 Prince Edward Island market estimates and forecasts, 2018 - 2030 (USD Million) (Volume, Number of Tests)
6.2.9 Quebec
6.2.9.1 Quebec market estimates and forecasts, 2018 - 2030 (USD Million) (Volume, Number of Tests)
6.2.10 Saskatchewan
6.2.10.1 Saskatchewan market estimates and forecasts, 2018 - 2030 (USD Million) (Volume, Number of Tests)
6.2.11 Nunavut
6.2.11.1 Nunavut market estimates and forecasts, 2018 - 2030 (USD Million) (Volume, Number of Tests)
6.2.12 Northwest Territories
6.2.12.1 Northwest Territories market estimates and forecasts, 2018 - 2030 (USD Million) (Volume, Number of Tests)
6.2.13 Yukon
6.2.13.1 Yukon market estimates and forecasts, 2018 - 2030 (USD Million) (Volume, Number of Tests)
6.2.14 Newfoundland & Labrador
6.2.14.1 Newfoundland & Labrador market estimates and forecasts, 2018 - 2030 (USD Million) (Volume, Number of Tests)
CHAPTER 7 CANADA LATENT TUBERCULOSIS INFECTION DETECTION MARKET - COMPETITIVE ANALYSIS
7.1 Strategy Framework
7.2 Market Participant Categorization
7.3 Recent Developments and Impact Analysis, by Key Market Participants
7.3.1 Ansoff matrix
7.4 Company Categorization
7.4.1 Innovators
7.4.2 Market Leaders
7.5 Vendor Landscape
7.5.1 List of key distributors and channel partners
7.5.2 Key customers
7.6 Public Companies
7.6.1 Company market position analysis
7.6.2 Competitive Dashboard Analysis
7.6.2.1 Market Differentiators
7.7 Private Companies
7.7.1 List of key emerging companies
7.8 Company Profiles
7.8.1 F. Hoffmann - La Roche Ltd.
7.8.1.1 Company overview
7.8.1.2 Financial performance
7.8.1.3 Product benchmarking
7.8.1.4 Strategic initiatives
7.8.2 Abbott
7.8.2.1 Company overview
7.8.2.2 Alere, Inc.
7.8.2.3 Financial performance
7.8.2.4 Product benchmarking
7.8.2.5 Strategic initiatives
7.8.3 QIAGEN
7.8.3.1 Company overview
7.8.3.2 Financial performance
7.8.3.3 Product benchmarking
7.8.3.4 Strategic initiatives
7.8.4 BD (Becton, Dickinson and Company)
7.8.4.1 Company overview
7.8.4.2 Financial performance
7.8.4.3 Product benchmarking
7.8.4.4 Strategic initiatives
7.8.5 bioM?rieux SA
7.8.5.1 Company overview
7.8.5.2 Financial performance
7.8.5.3 Product benchmarking
7.8.5.4 Strategic initiatives
7.8.6 Oxford Immunotec USA, Inc.
7.8.6.1 Company overview
7.8.6.2 Product benchmarking
7.8.6.3 Strategic initiatives
1.1 Market Segmentation and Scope
1.1.1 Regional scope
1.1.2 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database:
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective
1.10.2 Objective
1.10.3 Objective
1.10.4 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
CHAPTER 3 CANADA LATENT TUBERCULOSIS INFECTION DETECTION MARKET VARIABLES, TRENDS & SCOPE
3.1 Canada Latent Tuberculosis Infection Detection Market Lineage Outlook
3.1.1 Parent market outlook
3.1.2 Ancillary market
3.2 Penetration & Growth Prospect Mapping for Test Type
3.3 Market Dynamics
3.3.1 Market driver analysis
3.3.1.1 High migration rate in Canada
3.3.1.2 Increasing demand for tuberculosis testing
3.3.1.3 Government initiatives to control tuberculosis
3.3.2 Market restraint analysis
3.3.2.1 Lack of systematic approach to screen tuberculosis
3.3.2.2 Lack of proper recommendations and reimbursement policies
3.4 Regulatory & Reimbursement Scenario
3.5 Canada Latent Tuberculosis Infection Market Analysis Tools
3.5.1 Porter’s Five Forces Analysis
3.5.2 SWOT Analysis; By factor (Political & Legal, Economic, and Technological)
3.6 Prevalence Rate of Latent Tuberculosis Infection, by Province (2018 - 2030) (in Thousands)
3.7 Incidence Rate of Latent Tuberculosis Infection, by Province (2018 - 2030) (in Thousands)
3.8 Estimated Number of Active TB Patients, by Province (2018 - 2020)
3.9 Estimated Number of LTBI Patients, by Province (2018 - 2020)
3.10 Wholesaler’s Cost for the following Tests (2021)
CHAPTER 4 CANADA LATENT TUBERCULOSIS INFECTION DETECTION MARKET: SEGMENT ANALYSIS, BY TEST TYPE, 2018 - 2030 (USD MILLION) (VOLUME, NUMBER OF TESTS)
4.1 Canada Latent Tuberculosis Infection Detection Market: Test Type Movement Analysis
4.2 Segment Dashboard
4.2.1 Tuberculin Skin Test (TST)
4.2.1.1 TST market estimates and forecast, 2018 - 2030 (USD Million)
4.2.1.2 TST market estimates and forecast, 2018 - 2030 Number of Tests in Thousands
4.2.2 Interferon Gamma Release Assays (IGRA)
4.2.2.1 IGRA market estimates and forecast, 2018 - 2030 (USD Million)
4.2.2.2 IGRA market estimates and forecast, 2018 - 2030 Number of Tests in Thousands
CHAPTER 5 CANADA LATENT TUBERCULOSIS INFECTION DETECTION MARKET: SEGMENT ANALYSIS, BY END - USE, 2018 - 2030 (USD MILLION)
5.1 Canada Latent Tuberculosis Infection Detection Market: End - Use Movement Analysis
5.2 Segment Dashboard
5.2.1 Diagnostic Laboratories
5.2.1.1 Diagnostic laboratories market estimates and forecast, 2018 - 2030 (USD Million)
5.2.2 Hospitals & Clinics
5.2.2.1 Hospitals & clinics market estimates and forecast, 2018 - 2030 (USD Million)
5.2.3 Academic & Research Institutions
5.2.3.1 Academic & research institutions market estimates and forecast, 2018 - 2030 (USD Million)
CHAPTER 6 CANADA LATENT TUBERCULOSIS INFECTION DETECTION MARKET: SEGMENT ANALYSIS, BY PROVINCE, 2018 - 2030 (USD MILLION)
6.1 Regional Market Share Analysis, 2021 & 2030
6.2 Canada
6.2.1 Canada Market estimates and forecast, 2018 - 2030 (USD Million) (Volume, Number of Tests)
6.2.2 Alberta
6.2.2.1 Alberta market estimates and forecasts, 2018 - 2030 (USD Million) (Volume, Number of Tests)
6.2.3 British Columbia
6.2.3.1 British Columbia market estimates and forecasts, 2018 - 2030 (USD Million) (Volume, Number of Tests)
6.2.4 Manitoba
6.2.4.1 Manitoba market estimates and forecasts, 2018 - 2030 (USD Million) (Volume, Number of Tests)
6.2.5 New Brunswick
6.2.5.1 New Brunswick market estimates and forecasts, 2018 - 2030 (USD Million) (Volume, Number of Tests)
6.2.6 Nova Scotia
6.2.6.1 Nova Scotia market estimates and forecasts, 2018 - 2030 (USD Million) (Volume, Number of Tests)
6.2.7 Ontario
6.2.7.1 Ontario market estimates and forecasts, 2018 - 2030 (USD Million) (Volume, Number of Tests)
6.2.8 Prince Edward Island
6.2.8.1 Prince Edward Island market estimates and forecasts, 2018 - 2030 (USD Million) (Volume, Number of Tests)
6.2.9 Quebec
6.2.9.1 Quebec market estimates and forecasts, 2018 - 2030 (USD Million) (Volume, Number of Tests)
6.2.10 Saskatchewan
6.2.10.1 Saskatchewan market estimates and forecasts, 2018 - 2030 (USD Million) (Volume, Number of Tests)
6.2.11 Nunavut
6.2.11.1 Nunavut market estimates and forecasts, 2018 - 2030 (USD Million) (Volume, Number of Tests)
6.2.12 Northwest Territories
6.2.12.1 Northwest Territories market estimates and forecasts, 2018 - 2030 (USD Million) (Volume, Number of Tests)
6.2.13 Yukon
6.2.13.1 Yukon market estimates and forecasts, 2018 - 2030 (USD Million) (Volume, Number of Tests)
6.2.14 Newfoundland & Labrador
6.2.14.1 Newfoundland & Labrador market estimates and forecasts, 2018 - 2030 (USD Million) (Volume, Number of Tests)
CHAPTER 7 CANADA LATENT TUBERCULOSIS INFECTION DETECTION MARKET - COMPETITIVE ANALYSIS
7.1 Strategy Framework
7.2 Market Participant Categorization
7.3 Recent Developments and Impact Analysis, by Key Market Participants
7.3.1 Ansoff matrix
7.4 Company Categorization
7.4.1 Innovators
7.4.2 Market Leaders
7.5 Vendor Landscape
7.5.1 List of key distributors and channel partners
7.5.2 Key customers
7.6 Public Companies
7.6.1 Company market position analysis
7.6.2 Competitive Dashboard Analysis
7.6.2.1 Market Differentiators
7.7 Private Companies
7.7.1 List of key emerging companies
7.8 Company Profiles
7.8.1 F. Hoffmann - La Roche Ltd.
7.8.1.1 Company overview
7.8.1.2 Financial performance
7.8.1.3 Product benchmarking
7.8.1.4 Strategic initiatives
7.8.2 Abbott
7.8.2.1 Company overview
7.8.2.2 Alere, Inc.
7.8.2.3 Financial performance
7.8.2.4 Product benchmarking
7.8.2.5 Strategic initiatives
7.8.3 QIAGEN
7.8.3.1 Company overview
7.8.3.2 Financial performance
7.8.3.3 Product benchmarking
7.8.3.4 Strategic initiatives
7.8.4 BD (Becton, Dickinson and Company)
7.8.4.1 Company overview
7.8.4.2 Financial performance
7.8.4.3 Product benchmarking
7.8.4.4 Strategic initiatives
7.8.5 bioM?rieux SA
7.8.5.1 Company overview
7.8.5.2 Financial performance
7.8.5.3 Product benchmarking
7.8.5.4 Strategic initiatives
7.8.6 Oxford Immunotec USA, Inc.
7.8.6.1 Company overview
7.8.6.2 Product benchmarking
7.8.6.3 Strategic initiatives
LIST OF TABLES
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Canada latent tuberculosis infection detection market, by test type, 2018 - 2030 (USD Million)
Table 4 Canada latent tuberculosis infection detection market, by test type, 2018 - 2030 (Number of tests)
Table 5 Canada latent tuberculosis infection detection market, by end - use, 2018 - 2030 (USD Million)
Table 6 Alberta latent tuberculosis infection detection market, by test type, 2018 - 2030 (USD Million)
Table 7 Alberta latent tuberculosis infection detection market, by test type, 2018 - 2030 (Number of tests)
Table 8 Alberta latent tuberculosis infection detection market, by end - use, 2018 - 2030 (USD Million)
Table 9 British Columbia latent tuberculosis infection detection market, by test type, 2018 - 2030 (USD Million)
Table 10 British Columbia latent tuberculosis infection detection market, by test type, 2018 - 2030 (Number of tests)
Table 11 British Columbia latent tuberculosis infection detection market, by end - use, 2018 - 2030 (USD Million)
Table 12 Manitoba latent tuberculosis infection detection market, by test type, 2018 - 2030 (USD Million)
Table 13 Manitoba latent tuberculosis infection detection market, by test type, 2018 - 2030 (Number of tests)
Table 14 Manitoba latent tuberculosis infection detection market, by end - use, 2018 - 2030 (USD Million)
Table 15 New Brunswick latent tuberculosis infection detection market, by test type, 2018 - 2030 (USD Million)
Table 16 New Brunswick latent tuberculosis infection detection market, by test type, 2018 - 2030 (Number of tests)
Table 18 New Brunswick latent tuberculosis infection detection market, by end - use, 2018 - 2030 (USD Million)
Table 18 Nova Scotia latent tuberculosis infection detection market, by test type, 2018 - 2030 (USD Million)
Table 19 Nova Scotia latent tuberculosis infection detection market, by test type, 2018 - 2030 (Number of tests)
Table 20 Nova Scotia latent tuberculosis infection detection market, by end - use, 2018 - 2030 (USD Million)
Table 21 Ontario latent tuberculosis infection detection market, by test type, 2018 - 2030 (USD Million)
Table 22 Ontario latent tuberculosis infection detection market, by test type, 2018 - 2030 (Number of tests)
Table 23 Ontario latent tuberculosis infection detection market, by end - use, 2018 - 2030 (USD Million)
Table 24 Prince Edward Island latent tuberculosis infection detection market, by test type, 2018 - 2030 (USD Million)
Table 25 Prince Edward Island latent tuberculosis infection detection market, by test type, 2018 - 2030 (Number of tests)
Table 26 Prince Edward Island latent tuberculosis infection detection market, by end - use, 2018 - 2030 (USD Million)
Table 27 Quebec latent tuberculosis infection detection market, by test type, 2018 - 2030 (USD Million)
Table 30 Quebec latent tuberculosis infection detection market, by test type, 2018 - 2030 (Number of tests)
Table 29 Quebec latent tuberculosis infection detection market, by end - use, 2018 - 2030 (USD Million)
Table 30 Saskatchewan latent tuberculosis infection detection market, by test type, 2018 - 2030 (USD Million)
Table 31 Saskatchewan latent tuberculosis infection detection market, by test type, 2018 - 2030 (Number of tests)
Table 32 Saskatchewan latent tuberculosis infection detection market, by end - use, 2018 - 2030 (USD Million)
Table 33 Northwest Territories latent tuberculosis infection detection market, by test type, 2018 - 2030 (USD Million)
Table 34 Northwest Territories latent tuberculosis infection detection market, by test type, 2018 - 2030 (Number of tests)
Table 35 Northwest Territories latent tuberculosis infection detection market, by end - use, 2018 - 2030 (USD Million)
Table 36 Nunavut latent tuberculosis infection detection market, by test type, 2018 - 2030 (USD Million)
Table 37 Nunavut latent tuberculosis infection detection market, by test type, 2018 - 2030 (Number of tests)
Table 38 Nunavut latent tuberculosis infection detection market, by end - use, 2018 - 2030 (USD Million)
Table 39 Yukon latent tuberculosis infection detection market, by test type, 2018 - 2030 (USD Million)
Table 40 Yukon latent tuberculosis infection detection market, by test type, 2018 - 2030 (Number of tests)
Table 41 Yukon latent tuberculosis infection detection market, by end - use, 2018 - 2030 (USD Million)
Table 42 Newfoundland & Labrador latent tuberculosis infection detection market, by test type, 2018 - 2030 (USD Million)
Table 43 Newfoundland & Labrador latent tuberculosis infection detection market, by test type, 2018 - 2030 (Number of tests)
Table 44 Newfoundland & Labrador latent tuberculosis infection detection market, by end - use, 2018 - 2030 (USD Million)
Table 45 Leading market players anticipated to witness the highest growth
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Canada latent tuberculosis infection detection market, by test type, 2018 - 2030 (USD Million)
Table 4 Canada latent tuberculosis infection detection market, by test type, 2018 - 2030 (Number of tests)
Table 5 Canada latent tuberculosis infection detection market, by end - use, 2018 - 2030 (USD Million)
Table 6 Alberta latent tuberculosis infection detection market, by test type, 2018 - 2030 (USD Million)
Table 7 Alberta latent tuberculosis infection detection market, by test type, 2018 - 2030 (Number of tests)
Table 8 Alberta latent tuberculosis infection detection market, by end - use, 2018 - 2030 (USD Million)
Table 9 British Columbia latent tuberculosis infection detection market, by test type, 2018 - 2030 (USD Million)
Table 10 British Columbia latent tuberculosis infection detection market, by test type, 2018 - 2030 (Number of tests)
Table 11 British Columbia latent tuberculosis infection detection market, by end - use, 2018 - 2030 (USD Million)
Table 12 Manitoba latent tuberculosis infection detection market, by test type, 2018 - 2030 (USD Million)
Table 13 Manitoba latent tuberculosis infection detection market, by test type, 2018 - 2030 (Number of tests)
Table 14 Manitoba latent tuberculosis infection detection market, by end - use, 2018 - 2030 (USD Million)
Table 15 New Brunswick latent tuberculosis infection detection market, by test type, 2018 - 2030 (USD Million)
Table 16 New Brunswick latent tuberculosis infection detection market, by test type, 2018 - 2030 (Number of tests)
Table 18 New Brunswick latent tuberculosis infection detection market, by end - use, 2018 - 2030 (USD Million)
Table 18 Nova Scotia latent tuberculosis infection detection market, by test type, 2018 - 2030 (USD Million)
Table 19 Nova Scotia latent tuberculosis infection detection market, by test type, 2018 - 2030 (Number of tests)
Table 20 Nova Scotia latent tuberculosis infection detection market, by end - use, 2018 - 2030 (USD Million)
Table 21 Ontario latent tuberculosis infection detection market, by test type, 2018 - 2030 (USD Million)
Table 22 Ontario latent tuberculosis infection detection market, by test type, 2018 - 2030 (Number of tests)
Table 23 Ontario latent tuberculosis infection detection market, by end - use, 2018 - 2030 (USD Million)
Table 24 Prince Edward Island latent tuberculosis infection detection market, by test type, 2018 - 2030 (USD Million)
Table 25 Prince Edward Island latent tuberculosis infection detection market, by test type, 2018 - 2030 (Number of tests)
Table 26 Prince Edward Island latent tuberculosis infection detection market, by end - use, 2018 - 2030 (USD Million)
Table 27 Quebec latent tuberculosis infection detection market, by test type, 2018 - 2030 (USD Million)
Table 30 Quebec latent tuberculosis infection detection market, by test type, 2018 - 2030 (Number of tests)
Table 29 Quebec latent tuberculosis infection detection market, by end - use, 2018 - 2030 (USD Million)
Table 30 Saskatchewan latent tuberculosis infection detection market, by test type, 2018 - 2030 (USD Million)
Table 31 Saskatchewan latent tuberculosis infection detection market, by test type, 2018 - 2030 (Number of tests)
Table 32 Saskatchewan latent tuberculosis infection detection market, by end - use, 2018 - 2030 (USD Million)
Table 33 Northwest Territories latent tuberculosis infection detection market, by test type, 2018 - 2030 (USD Million)
Table 34 Northwest Territories latent tuberculosis infection detection market, by test type, 2018 - 2030 (Number of tests)
Table 35 Northwest Territories latent tuberculosis infection detection market, by end - use, 2018 - 2030 (USD Million)
Table 36 Nunavut latent tuberculosis infection detection market, by test type, 2018 - 2030 (USD Million)
Table 37 Nunavut latent tuberculosis infection detection market, by test type, 2018 - 2030 (Number of tests)
Table 38 Nunavut latent tuberculosis infection detection market, by end - use, 2018 - 2030 (USD Million)
Table 39 Yukon latent tuberculosis infection detection market, by test type, 2018 - 2030 (USD Million)
Table 40 Yukon latent tuberculosis infection detection market, by test type, 2018 - 2030 (Number of tests)
Table 41 Yukon latent tuberculosis infection detection market, by end - use, 2018 - 2030 (USD Million)
Table 42 Newfoundland & Labrador latent tuberculosis infection detection market, by test type, 2018 - 2030 (USD Million)
Table 43 Newfoundland & Labrador latent tuberculosis infection detection market, by test type, 2018 - 2030 (Number of tests)
Table 44 Newfoundland & Labrador latent tuberculosis infection detection market, by end - use, 2018 - 2030 (USD Million)
Table 45 Leading market players anticipated to witness the highest growth
LIST OF FIGURES
Fig. 1 Canada latent tuberculosis infection detection market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value - chain - based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Canada latent tuberculosis infection detection market outlook (2021)
Fig. 10 Penetration & growth prospect mapping, test type
Fig. 11 Market driver relevance analysis (Current & future impact)
Fig. 12 Market restraint relevance analysis (Current & future impact)
Fig. 13 Porter’s five forces analysis
Fig. 14 SWOT analysis
Fig. 15 Canada latent tuberculosis infection detection market: Test type outlook and key takeaways
Fig. 16 Canada latent tuberculosis infection detection market: Test type movement analysis
Fig. 18 Canada latent tuberculosis infection detection market: Test type segment dashboard
Fig. 18 Tuberculin skin test market estimates and forecast, 2018 - 2030 (USD million)
Fig. 19 Tuberculin skin test market estimates and forecast, 2018 - 2030 (tests in thousands)
Fig. 20 Interferon - gamma release assays market estimates and forecast, 2018 - 2030 (USD million)
Fig. 21 Interferon - gamma release assays market estimates and forecast, 2018 - 2030 (tests in thousands)
Fig. 22 Canada latent tuberculosis infection detection market: End - use outlook and key takeaways
Fig. 23 Canada latent tuberculosis infection detection market: End - use movement analysis
Fig. 24 Canada latent tuberculosis infection detection market: End - use segment dashboard
Fig. 25 Diagnostic laboratories market estimates and forecast, 2018 - 2030 (USD million)
Fig. 26 Hospitals & clinics market estimates and forecast, 2018 - 2030 (USD million)
Fig. 27 Academic & research institutions market estimates and forecast, 2018 - 2030 (USD million)
Fig. 28 Canada
Fig. 29 Canada market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Alberta
Fig. 31 Alberta market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 British Columbia
Fig. 33 British Columbia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Manitoba
Fig. 35 Manitoba market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 New Brunswick
Fig. 37 New Brunswick market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Nova Scotia
Fig. 39 Nova Scotia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Ontario
Fig. 41 Ontario market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Prince Edward Island
Fig. 43 Prince Edward Island market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Quebec
Fig. 45 Quebec market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 Saskatchewan
Fig. 47 Saskatchewan market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Nunavut
Fig. 49 Nunavut market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Northwest Territories
Fig. 51 Northwest Territories market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 Yukon
Fig. 53 Yukon market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 Newfoundland & Labrador
Fig. 55 Newfoundland & Labrador market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 56 Strategy framework
Fig. 57 Participant categorization
Fig. 58 Ansoff matrix
Fig. 59 Company market position analysis
Fig. 60 Company market position analysis
Fig. 61 Market differentiators
Fig. 1 Canada latent tuberculosis infection detection market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value - chain - based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Canada latent tuberculosis infection detection market outlook (2021)
Fig. 10 Penetration & growth prospect mapping, test type
Fig. 11 Market driver relevance analysis (Current & future impact)
Fig. 12 Market restraint relevance analysis (Current & future impact)
Fig. 13 Porter’s five forces analysis
Fig. 14 SWOT analysis
Fig. 15 Canada latent tuberculosis infection detection market: Test type outlook and key takeaways
Fig. 16 Canada latent tuberculosis infection detection market: Test type movement analysis
Fig. 18 Canada latent tuberculosis infection detection market: Test type segment dashboard
Fig. 18 Tuberculin skin test market estimates and forecast, 2018 - 2030 (USD million)
Fig. 19 Tuberculin skin test market estimates and forecast, 2018 - 2030 (tests in thousands)
Fig. 20 Interferon - gamma release assays market estimates and forecast, 2018 - 2030 (USD million)
Fig. 21 Interferon - gamma release assays market estimates and forecast, 2018 - 2030 (tests in thousands)
Fig. 22 Canada latent tuberculosis infection detection market: End - use outlook and key takeaways
Fig. 23 Canada latent tuberculosis infection detection market: End - use movement analysis
Fig. 24 Canada latent tuberculosis infection detection market: End - use segment dashboard
Fig. 25 Diagnostic laboratories market estimates and forecast, 2018 - 2030 (USD million)
Fig. 26 Hospitals & clinics market estimates and forecast, 2018 - 2030 (USD million)
Fig. 27 Academic & research institutions market estimates and forecast, 2018 - 2030 (USD million)
Fig. 28 Canada
Fig. 29 Canada market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Alberta
Fig. 31 Alberta market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 British Columbia
Fig. 33 British Columbia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Manitoba
Fig. 35 Manitoba market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 New Brunswick
Fig. 37 New Brunswick market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Nova Scotia
Fig. 39 Nova Scotia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Ontario
Fig. 41 Ontario market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Prince Edward Island
Fig. 43 Prince Edward Island market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Quebec
Fig. 45 Quebec market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 Saskatchewan
Fig. 47 Saskatchewan market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Nunavut
Fig. 49 Nunavut market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Northwest Territories
Fig. 51 Northwest Territories market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 Yukon
Fig. 53 Yukon market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 Newfoundland & Labrador
Fig. 55 Newfoundland & Labrador market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 56 Strategy framework
Fig. 57 Participant categorization
Fig. 58 Ansoff matrix
Fig. 59 Company market position analysis
Fig. 60 Company market position analysis
Fig. 61 Market differentiators
